APA (7th ed.) Citation

M, A., A, M., S, P., K, A., H, C., P, J., . . . GK, D. (2024). Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients? Clinical lung cancer, 25(6), 509. https://doi.org/10.1016/j.cllc.2024.05.003

Chicago Style (17th ed.) Citation

M, Awidi, Mier-Hicks A, Perimbeti S, Attwood K, Chen H, Jain P, Yau E, Early A, and Dy GK. "Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?" Clinical Lung Cancer 25, no. 6 (2024): 509. https://doi.org/10.1016/j.cllc.2024.05.003.

MLA (9th ed.) Citation

M, Awidi, et al. "Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?" Clinical Lung Cancer, vol. 25, no. 6, 2024, p. 509, https://doi.org/10.1016/j.cllc.2024.05.003.